Viridian Therapeutics, Inc. (0K1R.L)
USD 19.62
(-7.91%)
USD 19.62
(-7.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -234.56 Million USD | -81.91% |
| 2022 | -128.63 Million USD | -63.18% |
| 2021 | -78.79 Million USD | -96.53% |
| 2020 | -109.66 Million USD | 1.69% |
| 2019 | -40.75 Million USD | -28.93% |
| 2018 | -31.54 Million USD | -21.82% |
| 2017 | -25.82 Million USD | -175.48% |
| 2016 | -12.5 Million USD | 13.8% |
| 2015 | -11 Million USD | -61.26% |
| 2014 | -6.72 Million USD | -2190.38% |
| 2013 | -47.89 Thousand USD | 89.9% |
| 2012 | -3.88 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -55.89 Million USD | 27.42% |
| 2024 Q2 | -64.25 Million USD | -34.12% |
| 2023 Q2 | -54.76 Million USD | 19.45% |
| 2023 FY | - USD | -81.91% |
| 2023 Q3 | -51.22 Million USD | 6.47% |
| 2023 Q4 | -65.79 Million USD | -28.44% |
| 2023 Q1 | -67.98 Million USD | -49.04% |
| 2022 Q4 | -45.61 Million USD | -59.06% |
| 2022 Q2 | -29.28 Million USD | -13.27% |
| 2022 Q1 | -25.84 Million USD | 10.59% |
| 2022 FY | - USD | -63.18% |
| 2022 Q3 | -28.67 Million USD | 2.05% |
| 2021 Q2 | -17.96 Million USD | 2.51% |
| 2021 Q4 | -28.91 Million USD | -106.32% |
| 2021 FY | - USD | -96.53% |
| 2021 Q1 | -18.42 Million USD | 10.98% |
| 2021 Q3 | -14.01 Million USD | 21.99% |
| 2020 Q2 | -6.27 Million USD | 20.57% |
| 2020 Q3 | -5.4 Million USD | 13.96% |
| 2020 FY | - USD | 1.69% |
| 2020 Q4 | -20.7 Million USD | -283.28% |
| 2020 Q1 | -7.9 Million USD | 20.56% |
| 2019 Q3 | -11.02 Million USD | -27.22% |
| 2019 Q1 | -11.32 Million USD | -12.24% |
| 2019 FY | - USD | -28.93% |
| 2019 Q4 | -9.94 Million USD | 9.78% |
| 2019 Q2 | -8.66 Million USD | 23.46% |
| 2018 FY | - USD | -21.82% |
| 2018 Q4 | -10.08 Million USD | -15.69% |
| 2018 Q3 | -8.72 Million USD | -3.44% |
| 2018 Q2 | -8.43 Million USD | -92.36% |
| 2018 Q1 | -4.38 Million USD | 29.26% |
| 2017 Q1 | -6.83 Million USD | -24.36% |
| 2017 Q2 | -7.17 Million USD | -4.93% |
| 2017 Q3 | -5.69 Million USD | 20.58% |
| 2017 Q4 | -6.19 Million USD | -8.76% |
| 2017 FY | - USD | -175.48% |
| 2016 FY | - USD | 13.8% |
| 2016 Q1 | -2.68 Million USD | 9.1% |
| 2016 Q2 | -2.43 Million USD | 9.38% |
| 2016 Q3 | -1.76 Million USD | 27.38% |
| 2016 Q4 | -5.49 Million USD | -210.74% |
| 2015 FY | - USD | -61.26% |
| 2015 Q4 | -2.95 Million USD | 4.02% |
| 2015 Q2 | -2.44 Million USD | 4.75% |
| 2015 Q1 | -2.56 Million USD | -15.72% |
| 2015 Q3 | -3.08 Million USD | -26.01% |
| 2014 Q4 | -2.21 Million USD | -38.74% |
| 2014 FY | - USD | -2190.38% |
| 2014 Q1 | -130.58 Thousand USD | -144.8% |
| 2014 Q2 | -2.77 Million USD | -2025.26% |
| 2014 Q3 | -1.59 Million USD | 42.39% |
| 2013 Q1 | -41.8 Thousand USD | 0.0% |
| 2013 FY | - USD | 89.9% |
| 2013 Q4 | 291.5 Thousand USD | 206.11% |
| 2013 Q3 | -274.71 Thousand USD | -1100.63% |
| 2013 Q2 | -22.88 Thousand USD | 45.26% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -888.266% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | -33.524% |
| Codexis, Inc. | -49.28 Million USD | -375.955% |
| Organovo Holdings, Inc. | -14.8 Million USD | -1484.256% |